Catalyst Pharmaceuticals (CPRX) Tops Q1 EPS by 12c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Catalyst Pharmaceuticals (CPRX) Tops Q1 EPS by 12c, Revenues Beat

Catalyst Pharmaceuticals Announces First Quarter 2019 Financial Results and Provides Corporate Update

May 13, 2019 6:03 AM EDT

-Firdapse® Launch Off to Strong Start with First Quarter Net Revenues of $12.4 Million

-81 Patients Without Previous Access to any Form of Amifampridine Have Been Prescribed Firdapse

-Company to Host Quarterly Conference Call at 8:30 am ET Today

CORAL GABLES, Fla., May 13, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported financial results... More